Sponsored

Chimeric Therapeutics (ASX:CHM) launches Phase 1B clinical trial in glioblastoma

June 05, 2023 10:45 AM AEST | By Ankit Sethi
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Highlights

  • Multi-centre trial of CHM 1101 (CLXT CAR T) is activated at Sarah Cannon Research Institute in the US
  • Enrolment for Chimeric’s trial is open for people suffering from recurrent and/ or progressive glioblastoma multiforme (GBM)
  • GBM is stated to be the most common and also the deadliest primary brain cancer

ASX-listed Chimeric Therapeutics Limited (ASX: CHM) -- a developer of cellular therapies for treatment of cancer -- has announced the activation of CHM 1101 (CLXT CAR T) clinical trial (Phase 1B). The multi-centre trial (conducted under a US IND) of the cell therapy will evaluate the safety and efficacy of CHM 1101 in patients with recurrent and/ or progressive GBM.

Jason B Litten MD, Chief Medical Officer of CHM, has lauded the development and commented that the early clinical results of the therapy from the City of Hope trial were able to demonstrate that CHM 1101 may "improve outcomes" in glioblastoma multiforme.

Source: Company update

More

Australia's listed cellular therapy company Chimeric Therapeutics has informed about the launch of Phase 1B clinical trial for its CLTX CAR T therapy CHM 1101. The enrolment of patients, CHM states, is open at the Texas (US) located St. David’s South Austin Medical Center.

The trial involves people suffering from recurrent and/ or progressive glioblastoma (GBM). It is pertinent to note that GBM is considered the most common and also the most deadly primary brain cancer. Notably, the CHM 1101 trial is being undertaken under a US IND. It is a two-part process, in which Chimeric would establish a recommended Phase 2 dose and administration schedule.

The part A of CHM 1101 trial would involve up to six patients at the highest dose tested in the already ongoing trial being undertaken at the City of Hope Cancer Centre. Part B will follow the assessment of clinical safety and activity from the CHM 1101 trial (expected later this year). Part B is a dose expansion cohort, and it will involve enrolment of 12 to 26 additional patients.

Chimeric has also stated that once Part B is successfully completed, it intends to design and begin a registration trial, which will be in collaboration with global regulatory feedback.

Comments

Jennifer Chow, the CEO and Managing Director of the company, states that Phase 1B marks a "new chapter" in the progress of Chimeric's cell therapy CHM 1101. This is set to speed up the next phase of advancement if backed by positive outcomes.

CHM shares were trading over 2.6% higher at AU$0.038 at the time of writing (market cap over AU$17 million) at the time of writing on 8 June 2023.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Two ASX Listed Stocks Giving Bullish Indications

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.